Company intelligence / Profile preview

bioAffinity Technologies, Inc.

San Antonio, Texas, United Statesbioaffinitytech.com ↗

Ownership: Public · BIAF
Employees: ~57
Development stage: Commercial

Overview

CyPath® Lung, the company’s lead product, has demonstrated high sensitivity (~92%) and specificity (~87%) in detecting early-stage lung cancer in high-risk patients. The test uses a noninvasive sputum sample analyzed by advanced flow cytometry with AI. It has received a unique CPT code and reimbursement from Medicare/private insurers. A pivotal FDA clinical trial protocol was submitted in early 2025; commercial adoption continues to grow rapidly.

Therapeutic areas: OncologyPulmonology
Modalities: In vitro diagnostics (flow cytometry-based assay)Targeted cancer therapeutics
Industry: Biotech

Drug pipeline

1 asset

CyPath Lung

Commercial

Indications: Lung cancer

Partnerships

Collaborations with academic centers including University of Texas San Antonio; collection sites include academic/private/military/VA medical centers for clinical trials

Financials

Market cap: $3.9M
Total revenue: $1.5M
Enterprise value: $2.9M

Beyond the preview

Go deeper on bioAffinity Technologies, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bioAffinity Technologies, Inc..

Explore the full profile